Inhibikase Therapeutics (NASDAQ:IKT) reported its Q2 earnings results on Friday, August 12, 2022 at 04:00 PM.
Here’s what investors need to know about the announcement.
Earnings
Inhibikase Therapeutics beat estimated earnings by 5.26%, reporting an EPS of $-0.18 versus an estimate of $-0.19.
Revenue was down $1.36 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 1.63% increase in the share price the next day.
Here’s a look at Inhibikase Therapeutics’s past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.17 | -0.14 | -0.38 |
| EPS Actual | -0.18 | -0.20 | -0.18 | -0.22 |
| Revenue Estimate | 300K | 300K | 328K | 300K |
| Revenue Actual | 46K | 1.94M | 328K | 1.36M |
To track all earnings releases for Inhibikase Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
